Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Suenaga, Mitsukuni ^a   Nishina, Tomohiro ^b   Mizunuma, Nobuyuki ^a   Yasui, Hisateru ^c   Ura, Takashi ^d   Denda, Tadamichi ^e   Ikeda, Junichi ^f   Esaki, Taito ^g   Nishisaki, Hogara ^h   Takano, Yoshinao ⁱ   Sugiyama, Yasuyuki ^j   Muro, Kei ^d  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e CHIBA CANCER CENTER   (Japan)

^f Kitami Red Cross Hospital   (Japan)

^g NATIONAL KYUSHU CANCER CENTER   (Japan)

^h HYOGO CANCER CENTER   (Japan)

ⁱ Southern Tohoku General Hospital and Southern Tohoku Research Institute for Neuroscience   (Japan)

^j TEIKYO UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTICHOLINERGIC SYNDROME; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DNA POLYMORPHISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HETEROZYGOSITY; HUMAN; HYPERTENSION; INTERSTITIAL PNEUMONIA; JAPAN; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SEPSIS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TUMOR LOCALIZATION; VEIN EMBOLISM; VERY ELDERLY; VOMITING; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS;

EID: 84925825292     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1175-3     Document Type: Article

References (23)

1. Jemal A, Bray F, Melissa M. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Foundation for Promotion of Cancer Research. Cancer Statistics in Japan (2012). [http://ganjoho.jp/data/professional/statistics/backnumber/2012/cancer_statistics_2012.pdf] (15 January 2013, date last accessed).
3. Köhne CH, Schöffski P, Wilke H, Käufer C, Andreesen R, Ohl U, et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol. 1998;16:418-26.
4. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-47.
5. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
6. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR Study. J Clin Oncol. 2004;22:229-37.
7. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-45.
8. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-64.
9. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-83.
10. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26:5326-34.
11. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29-37.
12. Cohn AL, Bekaii-Saab T, Bendell JC, Hurwitz H, Kozloff M, Roach N, et al. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP) [abstract]. J Clin Oncol. 2010;28:3596.
13. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22:1382-8.
14. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M, et al. The role of UGT1A1*28 polymorphisms in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:3061-8.
15. Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, et al. Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci. 2011;102:1868-73.
16. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts III SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-44.
17. Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, et al. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study. Clin Colorectal Cancer. 2012;11:38-44.
18. Horita Y, Yamada Y, Kato K, Hirashima Y, Akiyoshi K, Nagashima K, et al. Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. Int J Clin Oncol. 2012;17:604-9.
19. Suenaga M, Matsusaka S, Ueno M, Yamamoto N, Shinozaki E, Mizunuma N, et al. Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients. Surg Today. 2011;41:1067-74.
20. Kubicka S, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol. 2013;24:2342-9.
21. Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012;48:1466-75.
22. Ishibashi K, Matsuda C, Tamagawa H, Munemoto Y, Tanaka C, Fukunaga M, et al. Randomized phase II study of oxaliplatin reintroduction and biweekly XELOX in previously treated patients with metastatic colorectal cancer (mCRC): ORION study [abstract]. Ann Oncol. 2013;49 Suppl 2:S559.
23. Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, et al. A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study): Reports of interim analysis [abstract]. J Clin Oncol. 2012;30:214.